Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pavurutamab - Amgen

Next Previous
Drug Profile

Pavurutamab - Amgen

Alternative Names: AMG 701 HLE-BiTE®; AMG-701

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; BeOne Medicines
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 23 Sep 2024 Amgen completed an Expanded Access Programme in Multiple myeloma (Second-line therapy or greater) in USA (NCT05256446)
  • 30 Jun 2023 Amgen completes a phase I/II trial for Multiple myeloma (Combination therapy, Monotherapy, Second line therapy or greater) in USA, the Netherlands, Australia, Belgium, Canada, Germany, Japan (IV) (NCT03287908) (EudraCT2017-001997-41) (JapicCTI205329)
  • 04 Aug 2022 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Netherlands, Japan, Germany, Australia, Canada, USA, Belgium (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top